Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Suresh S. Ramalingam, MD, on Clinical Implications of Using Nivolumab Plus Ipilimumab in First-Line NSCLC

Posted: Tuesday, June 30, 2020

Suresh S. Ramalingam, MD, of Emory University, talks about how the CheckMate 227 trial could alter first-line treatment for patients with advanced non–small cell lung cancer, in light of its 3-year overall survival data favoring nivolumab plus ipilimumab over chemotherapy.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.